RARE: Ultragenyx Pharmaceutical, Inc.
About
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Current Value
$44.911 Year Return
Current Value
$44.911 Year Return
Key Details
Market Cap
$4.17B
P/E Ratio
-6.98
1Y Stock Return
16.19%
1Y Revenue Growth
27.44%
Dividend Yield
0.00%
Price to Book
12.0
Strategies that include RARE
Stock's related to RARE
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRNX | 43.75% | $5.12B | +84.27% | 0.00% |
| PGEN | 42.16% | $228.91M | -28.00% | 0.00% |
| BFAM | 40.85% | $6.35B | +23.95% | 0.00% |
| DNLI | 40.33% | $3.50B | +33.66% | 0.00% |
| ARWR | 39.53% | $2.31B | -34.44% | 0.00% |
| CERS | 39.41% | $312.00M | -0.59% | 0.00% |
| FOLD | 38.66% | $2.84B | -11.52% | 0.00% |
| DNB | 38.48% | $5.29B | +20.54% | 1.69% |
| TILE | 38.39% | $1.45B | +150.00% | 0.16% |
| NTLA | 37.81% | $1.44B | -50.35% | 0.00% |
| ICFI | 37.71% | $2.50B | +3.50% | 0.41% |
| ORA | 37.30% | $4.80B | +20.68% | 0.61% |
| RVMD | 37.06% | $9.50B | +171.62% | 0.00% |
| RYTM | 36.77% | $3.69B | +79.50% | 0.00% |
| FLGT | 36.75% | $519.98M | -37.82% | 0.00% |
| RKT | 36.75% | $2.00B | +53.18% | 0.00% |
| PEB | 36.73% | $1.48B | +0.08% | 0.33% |
| BCRX | 36.72% | $1.49B | +41.37% | 0.00% |
| ALEX | 36.69% | $1.41B | +18.14% | 4.59% |
| AKR | 36.58% | $2.99B | +69.24% | 2.92% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| UNH | -<0.01% | $531.00B | +6.93% | 1.37% |
| POAI | -0.01% | $4.29M | -78.60% | 0.00% |
| CIVI | 0.02% | $4.91B | -21.31% | 3.94% |
| BTSG | -0.06% | $3.25B | +43.46% | 0.00% |
| PRPH | -0.09% | $18.14M | -82.61% | 0.00% |
| AIFU | -0.09% | $67.49M | -83.02% | 0.00% |
| CLMT | 0.10% | $1.79B | +35.14% | 0.00% |
| MSDL | -0.12% | $1.83B | +0.66% | 7.26% |
| TEO | 0.15% | $1.69B | +87.97% | 0.00% |
| NHTC | -0.16% | $61.83M | +0.19% | 14.81% |
| SEG | 0.16% | $319.72M | +12.41% | 0.00% |
| ARQ | 0.18% | $332.89M | +216.80% | 0.00% |
| CPSH | -0.19% | $20.70M | -40.13% | 0.00% |
| ARLP | -0.22% | $3.54B | +26.77% | 10.11% |
| OBDE | -0.27% | $1.82B | -2.27% | 4.76% |
| STNG | 0.28% | $2.96B | +0.87% | 2.75% |
| QTTB | -0.31% | $354.34M | +188.64% | 0.00% |
| USAC | -0.31% | $2.76B | -3.87% | 8.93% |
| KRRO | 0.32% | $436.84M | +20.68% | 0.00% |
| GO | -0.32% | $1.81B | -34.42% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HUSA | -16.64% | $16.69M | -11.56% | 0.00% |
| NNE | -12.65% | $833.66M | +531.50% | 0.00% |
| ADBE | -11.05% | $219.93B | -18.23% | 0.00% |
| TEM | -10.79% | $8.50B | 0.00% | 0.00% |
| BTCT | -10.16% | $42.61M | +353.33% | 0.00% |
| GAN | -9.14% | $83.39M | +21.19% | 0.00% |
| MCK | -8.40% | $78.15B | +35.51% | 0.42% |
| CYD | -7.84% | $364.46M | -2.94% | 4.26% |
| RBRK | -7.81% | $8.03B | +38.16% | 0.00% |
| SCKT | -6.94% | $10.88M | +15.32% | 0.00% |
| TCTM | -6.63% | $8.10M | -42.99% | 0.00% |
| NTZ | -6.51% | $47.64M | -30.94% | 0.00% |
| AGX | -6.47% | $2.01B | +224.91% | 0.85% |
| CHD | -6.38% | $27.18B | +19.50% | 1.03% |
| DK | -6.29% | $1.14B | -34.04% | 5.64% |
| TXO | -6.09% | $737.26M | -1.80% | 13.22% |
| PGR | -5.35% | $149.10B | +57.29% | 0.45% |
| UUU | -5.31% | $4.97M | -41.89% | 0.00% |
| COR | -4.83% | $47.48B | +21.20% | 0.86% |
| CAH | -4.76% | $28.64B | +12.14% | 1.70% |
ETF's related to RARE
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 57.41% | $6.58B | 0.35% |
| GNOM | 55.66% | $70.59M | 0.5% |
| PTH | 52.46% | $143.31M | 0.6% |
| IBB | 51.81% | $6.66B | 0.45% |
| FBT | 50.62% | $1.11B | 0.56% |
| XPH | 48.45% | $157.87M | 0.35% |
| BBH | 47.82% | $397.87M | 0.35% |
| PINK | 47.57% | $161.15M | 0.5% |
| PBE | 47.16% | $258.53M | 0.58% |
| FXH | 46.75% | $1.15B | 0.62% |
| IHE | 45.66% | $596.23M | 0.39% |
| VTWO | 43.45% | $12.38B | 0.1% |
| SMMV | 43.44% | $321.07M | 0.2% |
| FHLC | 43.38% | $2.73B | 0.084% |
| ESML | 43.11% | $1.90B | 0.17% |
| VHT | 43.08% | $17.06B | 0.1% |
| IWM | 43.07% | $75.73B | 0.19% |
| PRFZ | 42.92% | $2.65B | 0.39% |
| SIZE | 42.89% | $329.63M | 0.15% |
| FIW | 42.83% | $1.86B | 0.53% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| HIGH | 0.05% | $302.78M | 0.51% |
| COMT | -0.53% | $829.06M | 0.48% |
| PDBC | 0.61% | $4.40B | 0.59% |
| GSG | 0.64% | $914.42M | 0.75% |
| IBDP | -0.78% | $2.11B | 0.1% |
| KRBN | -0.88% | $242.47M | 0.85% |
| SOYB | 0.96% | $27.32M | 0.22% |
| AGZD | -1.06% | $142.76M | 0.23% |
| CANE | -1.09% | $17.72M | 0.29% |
| DBC | 1.43% | $1.39B | 0.87% |
| USCI | -1.44% | $185.47M | 1.07% |
| MINT | -1.46% | $11.62B | 0.35% |
| CORN | -1.52% | $61.12M | 0.2% |
| FMF | -1.79% | $244.61M | 0.95% |
| GBIL | 2.07% | $5.60B | 0.12% |
| FLRN | 2.12% | $2.33B | 0.15% |
| TBLL | 2.20% | $1.92B | 0.08% |
| TAIL | -2.71% | $67.98M | 0.59% |
| SHYD | 3.12% | $311.50M | 0.35% |
| ICLO | 3.17% | $209.30M | 0.2% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| USDU | -35.62% | $201.97M | 0.5% |
| UUP | -33.26% | $309.25M | 0.77% |
| BTAL | -27.23% | $388.04M | 1.43% |
| VIXY | -15.95% | $195.31M | 0.85% |
| EQLS | -12.97% | $76.08M | 1% |
| JBBB | -12.52% | $1.26B | 0.49% |
| KCCA | -9.85% | $220.51M | 0.87% |
| CTA | -9.19% | $350.27M | 0.78% |
| KMLM | -9.12% | $353.87M | 0.9% |
| BOXX | -8.99% | $4.43B | 0.1949% |
| TPMN | -8.30% | $40.60M | 0.65% |
| DBE | -7.63% | $50.13M | 0.77% |
| DBO | -7.35% | $217.57M | 0.77% |
| FLOT | -7.23% | $7.31B | 0.15% |
| FLTR | -7.20% | $1.79B | 0.14% |
| DBA | -7.00% | $755.88M | 0.93% |
| BILZ | -6.97% | $563.02M | 0.14% |
| WEAT | -5.35% | $120.27M | 0.28% |
| DBMF | -5.33% | $1.02B | 0.85% |
| HDRO | -3.81% | $164.26M | 0.3% |
News
Yahoo
NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 20,820 restricted stock units of the company’s common stock to 13 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Emplo
SeekingAlpha
Discover why Ultragenyx's strong earnings and promising pipeline make it a compelling investment opportunity in the rare disease market. Learn more on RARE stock here.
Finnhub
NOVATO - Ultragenyx Pharmaceutical Inc. today announced Phase data in support of the Phase 3 Aspire study for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, that will...
Yahoo
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 Phase 3 program on track to begin enrollment by end-of-year NOVATO, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, that will be presented at the 2024 Foundation for An
Finnhub
Ultragenyx Pharmaceutical Inc. announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, that will be presented...
Yahoo
Ultragenyx Pharmaceutical ( NASDAQ:RARE ) Third Quarter 2024 Results Key Financial Results Revenue: US$139.5m (up 42...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.